Real‐World Effectiveness of PCSK9 Inhibitors in Reducing LDL‐C in Patients With Familial Hypercholesterolemia in Italy: A Retrospective Cohort Study Based on the AIFA Monitoring Registries

Real‐World Effectiveness of PCSK9 Inhibitors in Reducing LDL‐C in Patients With Familial Hypercholesterolemia in Italy: A Retrospective Cohort Study Based on the AIFA Monitoring Registries

Background Information on the real‐world use of proprotein convertase subtilisin kexin 9 inhibitors (PCKS9is) in familial hypercholesterolemia are limited. We evaluated the pattern of prescription and the long‐term efficacy of alirocumab and evolocumab in Italian patients with familial hypercholeste...

Full description

Bibliographic Details
Main Authors: Marcello Arca, Simone Celant, Pier Paolo Olimpieri, Antonietta Colatrella, Luca Tomassini, Laura D'Erasmo, Maurizio Averna, Alberto Zambon, Alberico Luigi Catapano, Pierluigi Russo
Format: Article
Language:English
Published: Wiley 2023-11-01
Series:Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Subjects:
adherence
heterozygous familial hypercholesterolemia
homozygous familial hypercholesterolemia
LDL cholesterol
PCSK9 inhibitors
real‐world
Online Access:https://www.ahajournals.org/doi/10.1161/JAHA.122.026550

Internet

https://www.ahajournals.org/doi/10.1161/JAHA.122.026550

Similar Items